First
Treatment

Let Zemaira CareZ help you on your way to your first Zemaira treatment.

Alpha-1 assistance to help you get started

Upon enrollment in Zemaira CareZ, a CareZ Coordinator will contact you to help get you started on therapy.

If you are insured, we will help research your insurance coverage. Your CareZ Coordinator will contact your insurer on your behalf to determine your coverage. He or she will then be able to explain to you what your insurance will and won’t cover, including information about applicable co-pays and coverage limits. The CareZ team can also help with prior authorizations, appeals, or other insurance-related issues.

If you do not have insurance or your insurance does not cover Zemaira, your CareZ Coordinator will help you find a plan that works for you. CareZ will identify cost-effective insurance options that best meet your personal insurance needs. You will receive information not only about coverage for Zemaira but for your other medical needs and medications as well.

Additionally, your CareZ Coordinator may:

  • Refer you to financial assistance programs.
    Based on your type of insurance coverage and financial situation, your CareZ Coordinator may refer you to programs that can help you pay for your out-of-pocket treatment expenses or insurance premiums. If you do not have insurance coverage, they can still help you get access to treatment.

  • Connect you with a specialty pharmacy.
    Your CareZ Coordinator will connect you with the provider that will be responsible for administering your Zemaira on a weekly basis. Depending on your insurance coverage and your physician’s direction, you may receive your treatments in your home or at an infusion center. Your CareZ Coordinator can help you understand the options available to you.

  • Refer you to programs to ensure continued access to treatment.
    Be proactive and prepared for any unexpected lapses in insurance coverage by enrolling in the CSL Behring AssuranceSM loyalty program today. This program is available for privately insured individuals. It offers you peace of mind knowing you can continue on Zemaira, even during unexpected gaps in coverage due to your insurance not covering therapy, changing jobs, or switching insurance plans.

  • Refer you to nonprofit Alpha-1 support organizations.
    The CareZ community includes a network of not-for-profit organizations and advocacy groups that may be able to provide additional Alpha-1 assistance. In particular, CareZ works closely with AlphaNet to provide you with ongoing monthly support from fellow Alphas.

  • Transfer your prescription when needed.
    Life doesn’t stop just because you are on treatment. Your CareZ Coordinator will work with your specialty pharmacy if you move. Traveling? Your specialty pharmacy will help coordinate treatments when you’re away from home.

  • Provide insurance counseling during open enrollment periods.
    Your CareZ Coordinator can also provide insurance counseling during open enrollment periods to help you identify insurance plan option that take into consideration your Zemaira therapy, as well as any other prescriptions and medical needs that you may have.

Important Safety Information

Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated to raise the plasma level of alpha1-proteinase inhibitor (A1-PI) in patients with A1-PI deficiency and related emphysema. The effect of this raised level on the frequency of pulmonary exacerbations and the progression of emphysema have not been established in clinical trials.

Zemaira may not be suitable for everyone; for example, people with known hypersensitivity to components used to make Zemaira, those with a history of anaphylaxis or severe systemic response to A1-PI products, and those with certain IgA deficiencies. If you think any of these may apply to you, ask your doctor.

Early signs of hypersensitivity reactions to Zemaira include hives, rash, tightness of the chest, unusual breathing difficulty, wheezing, and feeling faint. Immediately discontinue use and consult with physician if such symptoms occur.

In clinical studies, the following adverse reactions were reported in at least 5% of subjects receiving Zemaira: headache, sinusitis, upper respiratory infection, bronchitis, fatigue, increased cough, fever, injection-site bleeding, nasal symptoms, sore throat, and swelled blood vessels.

Because Zemaira is made from human blood, the risk of transmitting infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information for Zemaira.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

CSL Behring

Zemaira is manufactured and distributed by CSL Behring LLC.
Zemaira® and CareZ® are registered trademarks of CSL Behring LLC.
CSL Behring AssuranceSM is a service mark of CSL Behring LLC.

© 2017 CSL Behring. The product information presented on this site is intended for US residents only.
ZMR14-04-0006 7/2014